AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$ARQT

Welgus Howard G. sold $124K of ARQT

Welgus Howard G. sold 4,730 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.18 ($0.12M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Welgus Howard G.
Published Aug 19, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The modest size and pre‑arranged 10b5‑1 plan suggest limited informational content for traders.

02

Market read

Minor insider sale with negligible trading impact.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: post-filing 2026-08-19

Background

Form 4 filings disclose insider transactions; this is a routine director sale.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Director Welgus Howard G. sold 4,730 shares of ARQT for $123,834 via a 10b5-1 plan.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

The transaction amount is small relative to float and typical insider activity, so market reaction is expected to be minimal.

Market effects

Sector

No immediate sector-wide implications; biotech sector remains unchanged.

Regional

US market only; no regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be purely portfolio rebalancing; investors might view it as non‑signal.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies.

  • Insider
    Welgus Howard G.

    Director of Arcutis Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

OCT 20
$ARQTHigh

Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb

Arcutis Biotherapeutics (ARQT) shares rose 10.65% to $31.89 after upgrades from Guggenheim and Cantor Fitzgerald, with price targets raised to $44 and $48 respectively. The company reported Q2 net income of $15M, up from a loss last year, driven by its eczema and psoriasis treatment Zoryve. ARQT raised its 2026 sales guidance to $525M-$540M. Institutional investors increased their holdings in Q2.

insidermonkey.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up

Arcutis Biotherapeutics (ARQT) shared new data on ZORYVE (roflumilast) and steroid use at dermatology conferences. Phase 2 data showed 34.4% of infants with atopic dermatitis achieved clear or almost clear skin after 4 weeks. Phase 3 data showed 66.4% of patients with scalp psoriasis achieved clear or almost clear skin at Week 8. The company also presented research on seborrheic dermatitis and corticosteroid hesitancy. ARQT stock was up 1.32% on Thursday and is up 1.84% in premarket trading.

rttnews.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis presents data on ZORYVE cream for infant eczema

Arcutis Biotherapeutics presented clinical trial data for ZORYVE cream in infants with eczema, showing 34.4% achieved clear or almost clear skin. The treatment had no serious adverse events. The company also shared data on ZORYVE foam for psoriasis, with 66.4% of patients achieving clear or almost clear scalp skin. Arcutis is seeking FDA approval for ZORYVE cream in infants, with a decision expected in 2027.

investing.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Biotherapeutics (ARQT) presented data on ZORYVE (roflumilast) at EADV and Fall Clinical Dermatology Conference. The company shared results from the INTEGUMENT-INFANT trial for infants with atopic dermatitis, ARRECTOR and DERMIS-1/2 trials for psoriasis, and collaborative research on seborrheic dermatitis. Additionally, Arcutis presented real-world data on topical corticosteroid use in chronic inflammatory skin conditions.

globenewswire.com2 min